Addressing the potential impact of novel coronavirus disease (COVID-19) on medicines supply in the EU

The EMA states no specific disruptions have yet been identified and that any impact in the short-term would be limited, given the current stocks in place. However, supply issues can be expected if lockdowns continue and/or other supply disruptions occur.

SPS commentary:

The EU (EMA, the European Commission and national competent authorities in the Member States) have organised the first meeting of the EU Executive Steering Group on shortages of medicines caused by major events to discuss measures aimed at addressing the impact of the outbreak of COVID-19 on the supply of medicines in the EU. In the context of COVID-19, the group will identify and coordinate EU-wide actions to protect patients when medicines in the EU are at risk of supply shortage, e.g. due to a temporary lockdown of manufacturing sites in areas affected by COVID-19 or travel restrictions impacting shipment.


European Medicines Agency